Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisA 10-year cohort analysis of routine paediatric ART data in a rural South African setting.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisA retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.Impact of earlier combination antiretroviral therapy on outcomes in children.Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.Insights into Adherence among a Cohort of Adolescents Aged 12-20 Years in South Africa: Reported Barriers to Antiretroviral Treatment.Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
P2860
Q21999480-A91B508A-0224-4576-9A94-2D527059CBA4Q31127942-88486965-C4FF-4364-9AE4-8C97237340BDQ33624953-4FBE1E14-80F4-4F1A-B9FE-3D8630824D82Q33884183-4D44C1F7-F626-482E-A739-9675398DDDECQ35599081-2D4327DD-2596-4325-9D99-DCA1B64CA3B7Q36501872-B0D1901D-8723-4D56-AA27-42EC6E3D0BECQ36558893-BCDF59B8-BB71-4638-AEC2-C5120A183E77Q37404721-CE0EBCCA-8CD8-48EC-8464-F6BB45B23037Q37544710-DA99FBF0-B79A-48C9-B873-41911376171BQ38239183-082A7F4B-40B5-4379-9454-6DE38B89AFC3Q47548671-F1D70725-1027-41B7-8F96-8BDFAA3113EA
P2860
Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Poor early virologic performan ...... ens for HIV-infected children.
@en
Poor early virologic performan ...... ens for HIV-infected children.
@nl
type
label
Poor early virologic performan ...... ens for HIV-infected children.
@en
Poor early virologic performan ...... ens for HIV-infected children.
@nl
prefLabel
Poor early virologic performan ...... ens for HIV-infected children.
@en
Poor early virologic performan ...... ens for HIV-infected children.
@nl
P2093
P2860
P50
P1476
Poor early virologic performan ...... ens for HIV-infected children.
@en
P2093
Erica Lazarus
Gary Reubenson
Gillian Sorour
Karl-Günter Technau
P2860
P304
P356
10.1097/INF.0B013E31828C3738
P577
2013-08-01T00:00:00Z